Browse Articles

Discover research articles across all indexed journals

Direct White–Light Reconfiguration of Dynamic Covalent Polymer Networks via Photoinsertable Spirothiopyran

Advanced Materials Shuailong Zhou, Mengqi Du, Zhaomiao Chu et al. Jul 01, 2026 DOI: 10.1002/adma.73573

ABSTRACT Light offers a powerful, noninvasive tool for polymer reprocessing and recycling. However, existing strategies predominantly rely on high–energy ultraviolet (UV) irradiation, which often induces material degradation and compromises the integrity of dynamic covalent networks. Herein, we report a white–light–activated addition reaction between spirothiopyran (STP) and poly(disulfide) that enables the direct structural reconfiguration of polymer networks. Upon illumination (λ > 400 nm), STP isomerizes to its ring–opened thiomerocyanine (TMC) form, exposing a reactive ene moiety, while the poly(disulfide) backbone homolytically dissociates into sulfur–centered radicals. These intermediates undergo rapid thiol–ene coupling, establishing dynamic C–S linkages. Notably, this process operates efficiently within bulk poly(disulfide) matrices, allowing the direct incorporation of STP into the polymer backbone and subsequent topological rearrangement of the network. The resulting photoinsertion introduces additional crosslinks, which not only enhance the mechanical properties and photostability but also enable spatiotemporal control over material welding, adhesion, remolding, and recycling. Furthermore, the synergy between STP photochromism and spatially controlled photocrosslinking unlocks advanced functionalities such as dual–color encryption and biomimetic morphogenesis. This work establishes a sustainable, visible–light–driven platform for polymer reconfiguration and opens new avenues toward smart, adaptable functional materials.

Olanzapine-based, dexamethasone-free antiemetic prophylaxis for highly emetogenic chemotherapy in children and adolescents: A multicenter phase III non-inferiority trial (CIVIC-POD).

Journal of Clinical Oncology Venkatraman Radhakrishnan, Prasanth Srinivasan, Gargi Das et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.304

304 Background: Guidelines recommend dexamethasone combined with a 5-HT3 receptor antagonist and a neurokinin-1 antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV) in children and adolescents receiving highly emetogenic chemotherapy (HEC); however, dexamethasone is associated with clinically significant toxicity. The effectiveness of olanzapine as a dexamethasone-sparing option in pediatric CINV prophylaxis remains unclear. Methods: CIVIC-POD (Chemotherapy Induced Vomiting in Children-Prophylaxis Omitting Dexamethasone) is an investigator-initiated, multicenter, open-label, phase III randomized non-inferiority trial (INPHOG-SUPP-22-03) that enrolled patients aged 4–18 years receiving HEC. Participants were randomized 1:1 for one cycle to dexamethasone, palonosetron, and fosaprepitant (DEX) or olanzapine, palonosetron, and fosaprepitant (OLANZ). The primary endpoint was complete response (CR) to vomiting (no vomiting or rescue antiemetics) during the overall phase (0–120 h). A non-inferiority margin of −15% was prespecified. With an assumed CR of 70%, 310 patients provided 80% power at a one-sided α of 0.025. Absolute differences were analyzed using the Miettinen–Nurminen method; non-inferiority required the lower bound of the 95% CI to exceed −15%. Results: Between December 2022 and January 2026, 310 patients were randomized (DEX, n=156; OLANZ, n=154); 299 were included in the per-protocol analysis (DEX, n=151; OLANZ, n=148). Median age was 13 years, and 56.8% received multi-day HEC. CR to vomiting during the overall period occurred in 56.9% of the DEX arm and 63.5% of the OLANZ arm (absolute difference 6.6%; 95% CI −4.5% to 17.7%), meeting non-inferiority criteria. Results were consistent in the intention-to-treat population. For secondary endpoints, CR to nausea during the overall period was similar between DEX and OLANZ (54.3% vs 53.4%). CR to vomiting during the acute period (0-24 h) was 64.2% vs 68.9%, and during the delayed period (24-120 h) was 78.8% vs 79.1%, in the DEX and OLANZ arms, respectively. CR to nausea during the acute period was 59.6% vs 59.5%, and during the delayed period was 69.5% vs 68.9%, respectively. Grade ≥2 toxicities were uncommon and similar. Somnolence was more frequent with OLANZ (52.0% vs 25.8%), with all events ≤ grade 2. Conclusions: Olanzapine-based, dexamethasone-free prophylaxis provided non-inferior vomiting control with similar nausea outcomes and acceptable toxicity, offering an evidence-based alternative to steroid-containing regimens in pediatric HEC. Clinical trial information: CTRI/2022/08/045009 .

Unlocking Efficient Spontaneous Deracemization: A MOF‐Mediated Heterogeneous System Overcomes Catalytic Incompatibility in Cocrystallization

Angewandte Chemie International Edition Xin Su, Jiaqiang Liu, Runyang Zhou et al. Jul 01, 2026 DOI: 10.1002/anie.3464047

ABSTRACT Cocrystallization‐induced deracemization is a powerful route to enantiopure pharmaceuticals, yet is hindered by detrimental interactions between homogeneous catalysts and chiral components. Herein, we report a novel heterogeneous catalysis strategy using metal–organic frameworks (MOFs) to overcome this compatibility challenge. By encapsulating the base catalyst 1,8‐diazabicyclo[5.4.0]undec‐7‐ene (DBU) into ZIF‐8, we created a ZIF‐8@DBU composite catalyst, that effectively isolates the catalyst while preserving its racemization activity. This enabled the efficient deracemization of racemic DMY via cocrystallization, selectively yielding either the (2 R ,3 R )‐ or (2 S ,3 S )‐enantiomer simply by switching the handedness of the coformer, N‐benzyl‐1‐phenylethylamine (NBP). Remarkably, the product yield reached up to 52%, surpassing the 50% theoretical limit of conventional chiral resolution techniques. The strategy proved general, extending successfully to ZIF‐67@DBU and ZIF‐90@DBU. This work demonstrates the feasibility of using tailored MOF composites to overcome long‐standing compatibility barriers in deracemization and opens avenues for their broader application in asymmetric synthesis.

Deep learning-based semantic segmentation of night-sky clouds for operational telescope scheduling

Scientific Reports Xuan Liu, Hai Cao, Ruojun Wang et al. Jul 01, 2026 DOI: 10.1038/s41598-026-56884-w

Abstract Ground-based optical telescopes necessitate prompt and spatially detailed information regarding dome-scale cloud coverage to facilitate target-specific shuttering and scheduling decisions. When only coarse or delayed atmospheric data are available, observatories risk inefficient use of scarce dark time and the irreversible loss of scientific exposures. To address this, we introduce the WOANC dataset, a pixel-annotated nighttime full-dome dataset acquired at an operational observatory, alongside NightCloudSegNet, a fisheye-aware segmentation framework specifically designed for low-light astronomical imaging. Evaluated on the WOANC test set, NightCloudSegNet achieves a mean intersection-over-union (mIoU) of 86.6% and a pixel-level F1 score of 92.8%. Furthermore, when tested on the external SWINSEG dataset, the model attains an mIoU of 86.2% and an F1 score of 92.6%, thereby demonstrating robust performance under conditions of fisheye distortion and low illumination. By translating pixel-level segmentation masks into per-target observability indicators, this approach has the potential to support informed shuttering and scheduling decisions, which is expected to enhance observational efficiency in automated telescope operations.

A Library of Dipolar Skyrmion Bags Observed in a Centrosymmetric van der Waals Magnet

Advanced Materials Yue Hu, Donghai Yang, Xuange Hu et al. Jul 01, 2026 DOI: 10.1002/adma.73589

ABSTRACT Topological magnetic solitons, such as skyrmions, exhibit topological protection and emergent electrodynamics that make them compelling for both fundamental research and spintronic applications. Beyond the canonical skyrmion, higher‐order and composite textures, such as skyrmion bag, offer arbitrary topological charges and internal morphology that critically governs their energetics and excitation dynamics. However, despite numerous theoretical proposals, experimental access to distinct skyrmion‐bag morphologies has so far been scarce and mainly confined to Dzyaloshinskii‐Moriya‐interaction (DMI)‐based systems. Here, we demonstrate a broad spectrum of skyrmion bags by using femtosecond‐laser excitation in a centrosymmetric van der Waals magnet Cr 1.6 Ti 0.03 Te 2 , referred to as dipolar skyrmion bags. The observed skyrmion bags are composed of closed domain‐wall loops with different circularities and varying loop numbers, as well as their corresponding type‐II counterparts, far beyond the limited skyrmion bags in DMI systems. Combining Lorentz transmission electron microscopy with micromagnetic simulations, we investigate in details their stability, circularity‐dependent field evolution, and distinct annihilation channels. This work substantially expands the experimentally accessible family of topological spin textures and pave the way toward multi‐state, reconfigurable spintronic functionalities based on dipolar skyrmion bags.

A two-step pre-treatment screening strategy combining enzyme phenotyping and targeted DPYD genotyping: A pragmatic approach for preventing fluoropyrimidine toxicity.

Journal of Clinical Oncology Joshua John Uzagare, Ajoy Oommen John, Ashish Singh et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.306

306 Background: Severe fluoropyrimidine toxicity is linked to reduced DPD activity. Universal DPYD genotyping has low sensitivity, high cost, long turnaround, and still fails to prevent toxicity in up to one-third of patients. Phenotyping with serum uracil and dihydrouracil:uracil (DHU:U) ratio is faster and more sensitive but less specific. We evaluated a two-step workflow—phenotyping all patients, then genotyping only phenotype-abnormal cases—to improve toxicity prediction and reduce genotyping requirements. Methods: In this study, 160 adults starting fluoropyrimidines underwent baseline fasting uracil and DHU:U testing. An abnormal phenotype was defined as uracil > 14.5 ng/mL or DHU:U < 6. The first 79 patients had universal DPYD phenotyping and genotyping; in the remaining patients, only abnormal phenotypes were genotyped. Grade ≥3 hematologic or gastrointestinal toxicities within cycles 1-3 were recorded along with dose reductions of 5-FU. Test performance for toxicity prediction was calculated for phenotype alone and the two-step strategy. Results: The median age was 47 (IQR 38–58), with 59% male and 73% having gastrointestinal cancers. Treatment included doublet chemotherapy (56%) and triplet (25%). Higher uracil increased toxicity risk (OR 1.15, p = 0.025); a higher DPYD activity score was protective (OR 0.79, p = 0.003). In the initial 79-patient cohort, 6 (7.6%) had an abnormal phenotype and 1 (1.2%) an abnormal genotype. Grade ≥3 toxicity occurred in 31 (39.2%): universal genotyping identified none, while the two-step strategy identified 4 (12.9%). No normal-phenotype patient with toxicity had an actionable variant. In the later 81-patient cohort undergoing two-step testing, 35 (43.2%) had an abnormal phenotype and 4 (4.9%) an abnormal genotype. Grade ≥3 toxicity was noted in 25 (30.8%), despite pre-emptive cycle 1 dose reduction in those with an abnormal phenotype (48.5%). In the Overall cohort (n = 160), 56 (35.0%) developed toxicity. The two-step strategy identified 16 (28.6%). Phenotype alone yielded 28.6% sensitivity, 76.2% specificity, 40.0% PPV, and 65.8% NPV. The two-step strategy improved specificity to 88.6% and PPV to 66.7%, keeping sensitivity and NPV unchanged. Under a sensitivity analysis projecting universal genotyping: assuming all untested were variant-negative gives 3/56 (5.4 %) identified; assuming all untested variant-positive gives 10/56 (17.9 %). We observed that only 2.8% of normal phenotype pateints with toxicity carried an actionable genotype variant. Conclusions: A two-step testing strategy predicts more severe toxicities, reduces genotyping requirements, and lowers costs compared to universal genotyping, offering a scalable, evidence-based method for safer fluoropyrimidine dosing.

Spontaneous, Catalyst‐Free Co‐Polymerization of Ionic Liquids With CO <sub>2</sub> Toward Polycarbonate

Angewandte Chemie International Edition Yongheng Cui, Ji Pan, Lang Yu et al. Jul 01, 2026 DOI: 10.1002/anie.8811376

ABSTRACT The conversion of carbon dioxide (CO 2 ) into value‐added polymer is a cornerstone of sustainable chemistry, yet current strategies typically require high pressures, metal catalysts, and yield materials with limited functionality. Herein, we report a spontaneous, catalyst‐free polymerization that directly converts CO 2 and hydroxyl‐functionalized ionic liquids (ILs) into multifunctional ionic polycarbonates under ambient conditions (0.1 MPa, 60°C). Mechanism studies, combining spectroscopic analysis and density functional calculations, elucidate a synergistic process wherein IL cations function as CO 2 concentrators, while OH − anions drive the polymerization via a bicarbonate‐mediated nucleophilic pathway. This approach yields a well‐defined ionic polycarbonate that uniquely integrates high ionic conductivity (&gt;10 − 4 S·m − 1 ), dual‐wavelength fluorescence, broad‐spectrum antibacterial activity (&gt;99% inhibition against E. coli and S. aureus ), and performance as a multifunctional adhesive enhancer with self‐monitoring capability. Furthermore, these polymers undergo complete degradation into monomeric constituents, establishing a closed‐loop monomer‐polymer‐monomer lifecycle. This work provides a paradigm for sustainable CO 2 valorization into advanced multifunctional materials, with immediate potential in smart adhesives, wearable electronics, and information encryption.

Real-time dynamic monitoring of rockfalls with PTZ cameras

Scientific Reports Shang Huang, Zongwang Yi, Xiaoqi Zhou et al. Jul 01, 2026 DOI: 10.1038/s41598-026-49008-x

Integrated analysis of miRNA–mRNA regulatory crosstalk: Insights from the miR-296-3p and DDHD2 network in breast cancer.

Journal of Clinical Oncology Ruqia Mehmood Baig, Nafeesa Kainat, Isha Rubab et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.61

61 Background: Breast cancer remains a leading cause of cancer-related morbidity and mortality among women worldwide, with exceptionally high incidence and death rates reported in Pakistan. Molecular biomarkers have gained considerable attention for their potential in improving early detection, prognostic evaluation, and therapeutic targeting. Among these, microRNAs and lipid-regulating genes play significant roles in tumor biology. The miR-296-3p has been described as both a tumor suppressor and an oncogenic regulator depending on cancer type, while DDHD2, a phospholipase A1 family gene involved in intracellular lipid metabolism, has recently been implicated as a proto-oncogene contributing to breast cancer aggressiveness. However, their expression patterns and clinical relevance in the Pakistani population remain largely unexplored. This study analyzed the expression of miR-296-3p and DDHD2 in fifty breast cancer and their adjacent normal tissue samples collected from hospitals in Rawalpindi, Islamabad, and Khyber Pakhtunkhwa. Methods: Ethical approval and informed consent were obtained prior to tissue collection. Total RNA was extracted, converted to cDNA by using commercially available kits, and quantified using quantitative real-time PCR. Relative expression was determined using the 2 ^ −ΔΔCt method, and statistical analyses including t-tests and Pearson correlations—were performed using SPSS software. Results: The results demonstrated that miR-296-3p expression was significantly overexpressed in breast cancer tissues compared with normal tissues (mean fold change: 62.34 vs. 1.65; p = 0.02). Similarly, DDHD2 expression was markedly upregulated in tumor tissues (20.39 vs. 1.16; p = 0.03).Correlation analyses revealed weak associations between these biomarkers and clinical variables such as estrogen receptor, progesterone receptor, HER2 status, tumor grade, age, and BMI. The correlation between miR-296-3p and DDHD2 expression was minimal, suggesting that their dysregulation occurs independently rather than through a shared pathway. Conclusions: Overall, the findings highlight that both miR-296-3p and DDHD2 are significantly elevated in breast cancer tissues in this regional cohort, indicating their potential involvement in tumor progression. Although clinical correlations were weak, the observed dysregulation underscores their possible utility as emerging molecular markers. Further functional investigations are required to clarify their biological roles and evaluate their suitability for diagnostic or therapeutic applications.

Metallaphotoredox‐Catalyzed Acceptorless Dehydrogenative Carbonylation Employing Benzylic C─H Bonds as Limiting Substrates

Angewandte Chemie International Edition Ling Li, Chuqian Tang, Guangying Huang et al. Jul 01, 2026 DOI: 10.1002/anie.9220846

ABSTRACT We report a visible light‐driven, metallaphotoredox‐catalyzed acceptorless dehydrogenative carbonylation of benzylic C─H bonds with carbon monoxide and nucleophiles. Enabled by a long‐chain diphosphine ligated nickel(II) bromide complex, this protocol uniquely employs C(sp 3 )─H bonds as limiting reagents under ambient temperature and CO atmosphere, affording esters and related carbonyls under oxidant‐free conditions with H 2 as the sole byproduct. The reaction exhibits broad substrate scope, tolerating diverse functional groups and complex bioactive scaffolds. Mechanistic studies are consistent with a pathway involving photoinduced hydrogen atom transfer and nickel‐mediated carbonylation.

Reducing skin tone bias in dermatology AI via sketch-guided multimodal fusion

Scientific Reports Muhammad Nasir, Muhammad Zeeshan Tahir, Shaohua Kevin Zhou Jul 01, 2026 DOI: 10.1038/s41598-026-59316-x

Abstract AI-driven skin lesion diagnosis systems are revolutionizing dermatology practice but perform worse on darker skin populations, which threatens diagnostic equity in dermatology. Existing debiasing strategies rely on explicit skin tone annotations or adversarial removal of demographic information, which may be unavailable in practice and can harm diagnostic accuracy. We aimed to design a dermatology AI system that reduces skin-tone-related performance disparities across diverse skin populations without using skin tone labels during training. We propose a novel sketch-guided multimodal fusion framework that combines color (RGB) images with algorithmically generated structural sketches. Separate encoders extract representations from each modality, which are integrated by a gated fusion module that adaptively weighs color and structure features. A feature distillation loss aligns color features with their sketch counterparts to encourage structure-aware representations while retaining clinically relevant color cues. We trained and evaluated the model on the Fitzpatrick17k and Diverse Dermatology Images (DDI) datasets. The fairness performance was assessed with Equalized Opportunity, Equalized Odds, and Predictive Quality Disparity across skin tone groups. Out-of-domain robustness was examined using a DermaAmin and Atlas Dermatologico split. On Fitzpatrick17k, the proposed model yielded competitive accuracy and F1-score, while showing lower mean disparity in fairness evaluation than baseline methods. It also demonstrated reduced subgroup disparity across skin tone groups on the evaluated fairness metrics. In the out-of-domain evaluation setup, the model also exhibited improved fairness. On the DDI dataset, the framework showed consistent performance across different skin tone groups with reduced variation. Our proposed model shows promise in reducing skin-tone-related bias in dermatology while preserving utility without relying on explicit skin tone annotations. The observed improvements in skin tone fairness across two datasets suggest that our approach may help reduce measured subgroup disparities in automated skin lesion assessment, although clinical utility and real-world impact remain to be established through prospective validation.

LEN-EOS study: Lenalidomide-associated eosinophilia as a marker of response to induction therapy in multiple myeloma.

Journal of Clinical Oncology Abhijith P. B., Akhil Santhosh Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.250

250 Background: Lenalidomide is an immunomodulatory drug which play an integral role in induction therapy in multiple myeloma. Treatment-emergent eosinophilia has been observed with immunomodulatory drugs, but its clinical significance in multiple myeloma (MM) remains uncertain. This study primarily evaluated the association between lenalidomide-induced eosinophilia and achievement of complete response, very good partial response or better (≥VGPR), over all response (≥PR), following bortezomib–lenalidomide–dexamethasone (VRd) induction in newly diagnosed multiple myeloma (NDMM). Methods: This prospective observational study was conducted between January 2022 and January 2025 at a tertiary cancer institute in India. NDMM patients treated with standard weekly VRd were included. Patients with baseline eosinophilia, active infection or allergy, renal and liver dysfunction were excluded. Absolute eosinophil count (AEC) was assessed at baseline and on Day 29 of cycle 1. Lenalidomide-induced eosinophilia was defined as an increase in AEC ≥250/µL from baseline. Responses were assessed according to International Myeloma Working Group criteria. Associations between eosinophilia and treatment response were evaluated using Fisher’s exact test and logistic regression. Results: Of 213 patients screened, 127 were included for analysis. Median age was 67 years; 84 patients (66.1%) were male and 43 (33.9%) were female. At diagnosis, 32.3% of patients had ISS stage I disease, 29.1% had stage II disease, and 38.6% had stage III disease. All patients received ≥4 cycles of VRd with full-dose lenalidomide. Lenalidomide-induced eosinophilia occurred in 20 patients (15.7%). Patients who developed eosinophilia demonstrated significantly higher response rates: CR was observed in 10 of 20 (50.0%) versus 29 of 107 (27.1%) (OR ~2.7; p = 0.04), ≥VGPR was achieved in 16 of 20 (80.0%) compared with 57 of 107 (53.3%) without eosinophilia (OR ~3.5; p = 0.01). Similarly, ≥PR was achieved in 19 of 20 (95.0%) compared with 78 of 107 (72.9%) (OR ~7.1; p = 0.03). Conclusions: Lenalidomide-induced eosinophilia is significantly associated with higher rates of complete response, deep response (≥VGPR), and overall response following VRd induction in NDMM. Early treatment-emergent eosinophilia may represent a simple, cost-effective biomarker of immune-mediated treatment efficacy and warrants further prospective validation.

Wrinkled Strain‐Enriched High‐Entropy Metallene Enables Cross‐Site Tandem Nitrate‐to‐Ammonia

Angewandte Chemie International Edition Tianfang Yang, Yang Liu, Menghao Kong et al. Jul 01, 2026 DOI: 10.1002/anie.5828704

ABSTRACT High‐entropy alloys (HEAs) are interesting for sustainable electrocatalytic nitrate‐to‐ammonia but suffer from low atom utilization and insufficient exposure of active sites. Here, we report a wrinkled PdFeCoNiCuIn high‐entropy metallene (HEM) that leverages a structural‐electronic dual regulation strategy to transcend these limitations. The incorporation of the p‐block element indium (In) triggers a strong p‐d orbital hybridization that synergizes with the intrinsic metallene architecture to construct a broad adsorption energy landscape. This architecture enables a cross‐site tandem catalytic pathway that spatially decouples nitrate activation from ammonia desorption, thereby circumventing scaling constraints. Consequently, the PdFeCoNiCuIn‐HEM delivers a remarkable ammonia Faradaic efficiency of 99.3% and a yield rate of 4.55 mmol h −1 mg cat −1 . Furthermore, the rechargeable Zn‐NO 3 − battery assembled with the PdFeCoNiCuIn‐HEM as cathode achieves a high open‐circuit voltage of 1.48 V, a power density of 7.36 mW cm −2 , and stable cycling over 100 h. This work provides a practical and generalizable design strategy for developing efficient NRA catalysts.

Growth need strength promotes employee creativity through work reflection with visionary leadership as a moderator

Scientific Reports Yonghua Liu, Jinnan Zhang, Shuyuan Tang et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59283-3

Abstract Employee creativity is crucial for organizations to maintain competitiveness. Although existing research has explored the relationship between employees’ growth need strength and creativity, the underlying connection between the two remains unclear. Based on trait activation theory, this study examines how visionary leadership, as an environmental cue, activates employees’ growth need strength, thereby promoting work reflection and creativity. Data were collected from 516 full-time employees across 111 teams using a three-phase, time-lagged design. Multilevel path analysis and Monte Carlo simulations were used to test the hypotheses. The results showed that employees’ growth need strength is positively related to creativity. Work reflection mediates the relationship between growth need strength and creativity. Visionary leadership strengthens the positive relationship between employees’ growth need strength and work reflection. Visionary leadership also moderates the mediating role of work reflection in the relationship between employees’ growth need strength and creativity. These findings contribute to the employee creativity literature by highlighting work reflection as an important mechanism and visionary leadership as a key contextual condition through which growth need strength promotes creativity.

Harnessing Corrosion in A P(VDF‐TrFE)/Mg Composite for Dynamic Passivation and Osteoimmunomodulation

Advanced Materials Weiwei Lao, Yanyan Li, Hongxiang Zhang et al. Jul 01, 2026 DOI: 10.1002/adma.73587

ABSTRACT Rather than suppressing corrosion, we propose “corrosion‐guided functionalization”, harnessing controlled Mg degradation as a programmable source of passivation and bioactivity. This concept is realized in an asymmetric, 3D‐interlocked P(VDF‐TrFE)/Mg mesh composite, where partial polymer encapsulation engineers interfacial micro‐crevices that act as in situ micro‐reactors. These micro‐reactors confine initial corrosion products, triggering autonomous growth of a dynamic, self‐adapting Mg(OH) 2 barrier. This passivation mechanism provides sustained corrosion stability compared to conventional sacrificial CaP coatings. Our composite achieves controlled corrosion that preserves the beneficial bioactivity of metallic Mg while avoiding the detrimental side effects that plague bare Mg. The composite exhibits robust antibacterial activity and reprograms the local immune microenvironment by polarizing macrophages toward a regenerative M2 phenotype through sustained corrosion‐derived Mg 2 + release and mild alkalinity. This immunomodulation triggers a downstream cascade, enhancing angiogenesis and neurogenesis, which collectively drive accelerated bone regeneration in a critical‐sized defect model. As a proof‐of‐concept, the composite thus serves as an advanced guided bone regeneration membrane, uniquely integrating sustained space maintenance with corrosion‐derived bioactivity and enabling minimally invasive retrieval after healing. Beyond this demonstration, this work establishes “corrosion‐guided functionalization” as a new strategy for corrosion control of biodegradable metals, offering a versatile tool for future biomaterial engineering.

Predictive value of clinical complete response to neoadjuvant chemotherapy in trimodality therapy for muscle invasive bladder cancer.

Journal of Clinical Oncology Bharath Kumar, Mihir Solanki, Priyamvada Maitre et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.185

185 Background: For patients with muscle-invasive bladder cancer (MIBC) treated with bladder-preserving trimodality therapy (TMT), the importance of response to neoadjuvant chemotherapy (NACT) is not known. Methods: The study cohort was drawn from a prospectively maintained institutional database of patients with non-metastatic MIBC treated with TMT from 2011 onwards. Eligibility criteria included NACT before TMT, pre- and post-NACT imaging available for review, and a minimum of 3 months of follow-up after TMT. Using pre- and post-NACT cystoscopy and imaging, each patient’s response was categorised as either clinical complete response (cCR), i.e. absence of any visible residual disease, or non-cCR, i.e. visible residual disease or suspicious thickening. All patients received 64Gy to the bladder using ‘plan of the day’ adaptive IMRT with daily image guidance and concurrent weekly chemotherapy. Bladder-intact event-free survival (BIEFS; time to invasive local recurrence, nodal or metastatic disease, any-cause cystectomy, or death) and overall survival (OS) were estimated from the date of completion of radiotherapy, and impact of cCR analysed using Cox proportional hazards model. Results: A total of 120 patients were analyzable (85% urothelial, 15% with variant subtype). Median age was 57 years (IQR 50-63), and most had cT2-T3 (89%) and N0 (62.5%) stage at diagnosis. NACT was predominantly 3-weekly gemcitabine and cisplatin (86.7%) for a median of 4 cycles (IQR 3-4). Post-NACT, 63% of patients attained cCR. All patients completed TMT as planned. Over a median follow up of 27 months, 35 events for BIEFS were observed. Overall 2-year BIEFS was 72.7%, significantly higher for patients with cCR vs non-cCR (80.9% vs 58.2%, p =0.04). cCR maintained statistical significance for BIEFS after adjusting for age, tumour and nodal stage [HR 0.49 (0.24- 1.0), p=0.05]. Total 22 patients died, with 2-year OS being 88% for cCR and 74% for non-cCR [HR 0.4(95% CI 0.16–0.99), p=0.05]. Conclusions: Post-NACT cCR effectively predicted improved outcomes, with significantly higher BIEFS for patients with MIBC treated with TMT.

Supramolecular Modulation of Photoinduced Charge Transfer: Tuning Between Tunneling and Incoherent Hopping

Angewandte Chemie International Edition Xueze Zhao, Guangcheng Wu, Chun Tang et al. Jul 01, 2026 DOI: 10.1002/anie.6007000

ABSTRACT Photoinduced charge transfer (CT) underpins photosynthesis and solar energy conversion technologies. However, achieving comprehensive control over CT in traditional covalent donor−bridge−acceptor (D−B−A) systems remains challenging, hindered by tedious organic synthesis and limited tunability. In this investigation, we harness molecular recognition to regulate photoinduced CT—including charge separation and recombination—leveraging its facile preparation and dynamic reversibility. By integrating guest molecules with a wide range of frontier orbital energies into a rigid cyclophane host ( DAPPTTzBox 4+ ), which features directional photoinduced intramolecular CT through cofacially stacked chromophores, we achieve comprehensive modulation of CT within well‐defined supramolecular complexes. This modulation spans mechanisms from tunneling to incoherent hopping. Notably, molecular recognition accelerates charge separation in DAPPTTzBox 4+ by 5.9‐ to 230‐fold, shifting from single‐step superexchange to multistep incoherent charge shift, while charge recombination rates are decreased (from 1.3‑ to 2.8‑fold) in superexchange systems. Additionally, guest‐induced charge trapping was also successfully demonstrated. This research exemplifies a fresh strategy for manipulating CT dynamics via noncovalent interactions, opening new avenues for the design of advanced artificial light‐harvesting materials.

Thermal management of pouch-type lithium-ion batteries using aluminum oxide porous media filled with nano-enhanced PCM

Scientific Reports Fares Suliaman Alromithy, Ali B. M. Ali, Omar J. Alkhatib et al. Jul 01, 2026 DOI: 10.1038/s41598-026-57286-8

Multi-mechanism armored B7H3/IL13Ra2 bispecific CAR-T for treatment of glioblastoma.

Journal of Clinical Oncology Keming Zhang, Ning Jiang, Weijun Sha et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.70

70 Background: Glioblastoma (GBM) is an aggressive and highly lethal cancer characterized by diffuse infiltration, molecular heterogeneity, immune evasion, and therapeutic resistance. Clinical outcomes remain poor due to antigen heterogeneity, an immunosuppressive tumor microenvironment, and limited access of targeted therapies across the blood–brain barrier. Despite early signals of activity with CAR-T therapy, sustained responses have not been achieved. We report the development of EPC-003, a fully human bispecific B7-H3/IL13Rα2 CAR-T product incorporating multi-mechanism armor to address antigen heterogeneity, reprogram the tumor microenvironment, and promote long-term persistence through central memory T-cell enrichment. Methods: A mechanism fine-tuned IL-2 variant with immune cell–type selectivity was discovered using a unique cytokine engineering platform and fused to an anti–PD-L1 scFv to generate a bispecific, multi-mechanism immune modulator. In parallel, target-binding scFvs against IL13Rα2 and B7-H3 were identified from proprietary human B-cell libraries using an mRNA display platform. Integration and optimization of these functional and binding modules yielded EPC-003, a bispecific tandem CAR targeting IL13Rα2, B7-H3, and incorporating a secreted multi-mechanism armor. EPC-003 mechanisms, antitumor potency, and preclinical safety were assessed. A scalable clinical manufacturing process was established to yield a central memory T cell–enriched CAR-T product. Results: The soluble armor demonstrated significant reduction of regulatory T-cell activation, while selectively activating central memory T-cells and mediating tumor infiltration lymphocytes in animal models, with the potential to improve CAR-T cell durability. In orthotopic GBM models, intracranial administration of low dose of EPC-003 (0.4 × 10⁶, 1.2 × 10⁶, 2 × 10⁶ CAR-T cells) induced tumor regression and showed dose-dependent anti-tumor activity. In a 7-day G-Rex manufacturing process, EPC-003 demonstrated promising druggability with robust and reproducible CAR expression, and the proprietary cytokine cocktail consistently enriched the product to &gt;65% central memory CAR-T cells in normal donors and GBM patients. In preclinical toxicity studies, EPC-003 exhibited a favorable safety profile, with no body weight loss, cytokine release syndrome, or systemic clinical signs. No treatment-related pathological changes were observed across 25 examined organs. Immunohistochemistry revealed no evidence of brain hemorrhage in treated groups, with minimal monocyte infiltration in the pia mater observed only at the high dose. Conclusions: EPC-003, a multi-mechanism armored bispecific CAR-T, demonstrated favorable preclinical safety, developability, robust anti-tumor activity, and potential durability. These data had supported its advancement into clinical trial for the treatment of glioblastoma.

Outside Back Cover: Unlocking Efficient Spontaneous Deracemization: A MOF‐Mediated Heterogeneous System Overcomes Catalytic Incompatibility in Cocrystallization (Angew. Chem. Int. Ed. 27/2026)

Angewandte Chemie International Edition Xin Su, Jiaqiang Liu, Runyang Zhou et al. Jul 01, 2026 DOI: 10.1002/anie.2026-m0506072700